The CYP11B2 gene, which encodes aldosterone synthase, has also been implicated in the development of hypertension and resistant hypertension by affecting aldosterone production and decreased response to spironolactone, a mineralocorticoid receptor antagonist commonly used in the treatment of resistant hypertension (78). This evidence concerns the gene CYP11B2 and Hypertension resistant to conventional therapy.